| HOME >> BIOLOGY >> TECHNOLOGY |
Dr. Michael Boyce-Jacino, president and CEO of BioNanomatrix added, "The approach covered in this new patent functions like the toll booth on a highway, serving in real time to separate and organize the random mix of vehicles comprising the flow of traffic down into single elements. Similarly, our nanofluidics chip system sorts the random flow of sample components down to the single molecule level, thereby enabling structural and functional analyses that would otherwise not be possible."
The NANOANALYZER is an integrated system that for the first time enables pan-genomic identification and analysis on a molecule-by-molecule basis, delivering single molecule sensitivity in a highly parallel format. It is designed to provide ultra high-resolution analyses of DNA, RNA and other proteins more rapidly, comprehensively and cost effectively than currently available approaches, with potential applications in diagnostics, personalized medicine and biomedical research.
US Patent No.: US 7,217,562 B2, Cao et al., May 15, 2007 was issued to Princeton University. BioNanomatrix is the exclusive licensee of the technology covered by this patent.
About BioNanomatrix
BioNanomatrix is developing breakthrough nanoscale whole genome imaging
and analytic platforms for applications in clinical genetics, cancer
diagnostics and other biomedical applications. The company is applying its
expertise in nanochips, nanodevices and nanosystems to develop its patented
platform technology to provide fast, comprehensive, and low-cost analysis
of genomic, epigenomic and proteomic information with sensitivity at the
single cell/single molecule level. BioNanomatrix' technologies are licensed
exclusively from Princeton University. Founded as a spin-out of Princeton
University in 2003, the company is headquartered in Philadelphia,
Pennsylvania. For more information, visit:
| SOURCE BioNanomatrix Copyright©2007 PR Newswire. All rights reserved |